Insights Blog @ Avulux
Avulux Added into the FDA-Funded Consortium for Technology & Innovation in Pediatrics (CTIP) Portfolio
Avulux, the innovator behind the only clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks, today announced that the Consortium for
Avulux and PECAA Partner to Bring Migraine Solution Lenses to Private Practices
Avulux, the maker of the only clinically proven migraine and light sensitivity lenses, and PECAA (Professional Eye Care Associates of America) are pleased to announce
Avulux Patient Feedback: Get Your Patients Back to What They Love
Migraine is a genetic neurological disease that affects nearly 48 million people in the United States — that’s almost 1 in 5 patients in your practice.
Avulux Proudly Partners with Opti-Port and PERC
Avulux is proud to announce formal partnerships with Opti-Port, the eye care industry’s only alliance of growth-oriented, multi-office eye care practices, and with PERC, a
A Neuro-Ophthalmologist’s Perspective On Migraine Prevalence In The Patient Population
Guest ContributorBradley Katz, MD, PhDMoran Eye Center Severe headache, nausea, sensitivity to light and sound, vision loss, depression, fatigue. For the nearly 48 million Americans
Eyenavision And Avulux Introduce Chemistrie Avulux Clips For People Living With Migraine And Light Sensitivity
Partnership between Eyenavision and Avulux offers elevated patient care and accelerated practice growth opportunities for eyecare providers PITTSBURGH/MIAMI – Aug. 19, 2024 – Eyenavision and